Arcus Biosciences, Inc.
RCUS
$10.53
$0.050.48%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.68% | -69.26% | 7.82% | 7.85% | 13.24% |
| Total Depreciation and Amortization | 11.11% | 11.11% | 25.00% | 66.67% | 28.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.71% | -28.05% | 26.56% | 20.90% | 20.59% |
| Change in Net Operating Assets | -20.22% | 131.43% | 130.99% | 130.88% | 5.32% |
| Cash from Operations | -37.25% | -42.86% | 44.44% | 45.14% | 19.28% |
| Capital Expenditure | 85.00% | 88.00% | 75.00% | 38.89% | -100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 512.77% | 251.90% | -135.78% | -141.56% | -120.00% |
| Cash from Investing | 385.07% | 212.50% | -143.30% | -150.23% | -129.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -37.76% | -42.53% | 618.18% | 558.33% | 630.30% |
| Repurchase of Common Stock | -500.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00% | -27.20% | 739.39% | 587.80% | 531.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 224.32% | 113.21% | 129.11% | 150.00% | -72.09% |